Skip Navigation LinksHome > February 10, 2010 - Volume 32 - Issue 3 > FDA Fast Track Designation for Myocet for Metastatic Breast...
Oncology Times:
doi: 10.1097/01.COT.0000368457.66658.a6
News

FDA Fast Track Designation for Myocet for Metastatic Breast Cancer

Free Access

The Food and Drug Administration has granted Fast Track status to nonpegylated liposomal doxorubicin (Myocet, made by Sopherion Therapeutics) for first-line therapy of HER2-positive metastatic breast cancer, which has shown reduced cardiotoxicity compared with traditional doxorubicin.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share